• search

Ranbaxy successfully invalidates Atorvastatin patent

Written by: Staff
|

Mumbai, Apr 26: Ranbaxy Pharmaceuticals has announced that a five-judge panel of the Supreme Patent and Trademark Board of Austria (OPM) has unanimously affirmed an earlier ruling of the Austrian Patent Office, which has invalidated claims (1-3) sought by Ranbaxy against Pfizer's Austrian Patent (AT 207896) covering Atorvastatin calcium (Lipitor).

On March 29 last year, the patent office had ruled (AT 207896) invalid for lack of novelty over Pfizer's international patent application and lack of inventive step over United States patent No 4,681,893, a company release said to BSE today.

''We are Pleased with the decision rendered by the Supreme Patent and the Trademark Board of Austria'' said Ranbaxy's Managing Director Malvinder Singh.

''Our success further validates our strategy to successfully commercialise Atorvastatin in Austria, and potentially other healthcare markets in future. It is anticipated that this will have a positive impact on healthcare costs by providing high quality, generic alternative at affordable prices,'' he further added.

UNI

For Daily Alerts

For Breaking News from Oneindia
Get instant news updates throughout the day.

Notification Settings X
Time Settings
Done
Clear Notification X
Do you want to clear all the notifications from your inbox?
Settings X
X
We use cookies to ensure that we give you the best experience on our website. This includes cookies from third party social media websites and ad networks. Such third party cookies may track your use on Oneindia sites for better rendering. Our partners use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on Oneindia website. However, you can change your cookie settings at any time. Learn more